Abstract MS2-3: Implications for clinical care

Abstract

Abstract Late recurrence, commonly considered to be distant recurrence five or more years after initial diagnosis remains a formidable challenge in breast oncology. Current management focuses on slowing the growth of macroscopic recurrent disease which is generally considered incurable. Emerging tools to identify minimal residual disease or tumor dormancy hold great promise to transform the treatment landscape in this space. This mini-symposium discussion will review the scope of the clinical challenge, highlighting the numbers at risk and the timeframe for recurrence risk. Current and emerging tools to assess the risk in individual patients beyond 5 years from diagnosis will be discussed. Evidence and guidelines on the use of clinically available anatomic-based and genomic assay-based late risk assessment tools including Clinical Treatment Score post-5 years (CTS5) and the Breast Cancer Index (BCI) will be highlighted. Current data on the role of circulating biomarkers including ctDNA, to identify at risk patients will be discussed as will open questions on how this might impact treatment approach. Finally, possible therapeutic approaches following the identification minimal residual or dormant disease will be reviewed, as will trial design options in this rapidly evolving space in breast oncology. Citation Format: Alexandra Thomas. Implications for clinical care [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr MS2-3.